Biogen Idec, Inc. Company Profile | BIIB Company Information

antoninahubihe.blogspot.com
Biogen Idec creates new standards of care in therapeutic areas with high unmertmedical needs. Founded in 1978, Biogen Idec is a global leader inthe discovery, development, manufacturing and commercialization of innovative Patients in more than 90 countries benefift from Biogen Idec's significant products that address diseasesd such as multiple sclerosis (MS), lymphoms and rheumatoid arthritis. In 2008, Biogenm Idec's total revenues grew 29 percent over 2007to $4.1 Currently, the company markets three major therapies and its produc development pipeline includes 20 products in Phase 2 clinicap trials and beyond.
Our majotr products include TYSABRI (natalizumab), the most recently approved treatmeng for relapsing formsof MS; AVONEXd (Interferon beta-1a), the No. 1 prescribe therapy for relapsing forms of MS andRITUXAN (rituximab), the world'ss most prescribed therapy for non-Hodgkin'ds lymphoma and marketed for the firsf time in 2006 for rheumatoixd arthritis. AVONEX and RITUXAN have for yearx ranked among the top 10 biotechnology productswsold globally.
In recent years, we also have leveraged our core capabilities to expand development into promisintg newtherapeutic areas, such as cardiovascular disease and Biogen Idec is headquartered in Cambridge, with international headquarters in Zug, Switzerland. We have additionao offices in the U.S., Canada, Japan and throughout Europe. ...